Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Accounts Payables (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Accounts Payables readings, the most recent being $674.3 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 46.08% to $674.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $674.3 million, a 46.08% increase, with the full-year FY2025 number at $674.3 million, up 46.08% from a year prior.
  • Accounts Payables hit $674.3 million in Q4 2025 for Neurocrine Biosciences, up from $584.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $674.3 million in Q4 2025 to a low of $171.9 million in Q1 2021.
  • Median Accounts Payables over the past 5 years was $375.0 million (2023), compared with a mean of $374.7 million.
  • Biggest five-year swings in Accounts Payables: skyrocketed 68.91% in 2023 and later dropped 21.93% in 2024.
  • Neurocrine Biosciences' Accounts Payables stood at $225.8 million in 2021, then skyrocketed by 53.94% to $347.6 million in 2022, then rose by 29.11% to $448.8 million in 2023, then increased by 2.85% to $461.6 million in 2024, then skyrocketed by 46.08% to $674.3 million in 2025.
  • The last three reported values for Accounts Payables were $674.3 million (Q4 2025), $584.3 million (Q3 2025), and $489.5 million (Q2 2025) per Business Quant data.